Anido Herranz Urbano, Fernández Calvo Ovidio, Afonso Afonso Francisco Javier, Rodríguez Martínez de Llano Sofía, Lázaro Quintela Martín, León Mateos Luis, Vázquez Estévez Sergio, Antón Aparicio Luis Miguel
Medical Oncology Department, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela 15706, Spain.
Expert Rev Anticancer Ther. 2015 Mar;15(3):339-48. doi: 10.1586/14737140.2015.999045. Epub 2015 Jan 2.
Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to demonstrate an improvement in overall survival and time to first symptomatic skeletal event in patients with castration resistant prostate cancer with symptomatic bone metastases. This fact has created a new paradigm in the treatment of prostate cancer landscape, where only chemotherapy and hormone therapy had a role, while β-emitters had been confined exclusively to the role of pain relief with no impact on survival. The aim of this review is to outline current treatment approaches for advanced prostate cancer with a focus on the role of radium-223 dichloride, reviewing patients' profile that make them suitable to therapy and chances for further studies.
放射性核素已广泛应用于癌症治疗。最近，针对二氯化镭-223在前列腺癌方面开展了新的研究，结果显示它是首个能改善去势抵抗性前列腺癌伴症状性骨转移患者总生存期及首次出现症状性骨骼事件时间的放射性药物。这一事实在前列腺癌治疗领域开创了新的模式，此前该领域只有化疗和激素疗法发挥作用，而β发射体仅局限于缓解疼痛，对生存期无影响。本综述的目的是概述晚期前列腺癌的当前治疗方法，重点关注二氯化镭-223的作用，回顾适合该疗法的患者特征以及进一步研究的机会。
